Clinical trials: Inflammatory Breast Carcinoma
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
This 4 arm study will evaluate the efficacy and safety of 4 neoadjuvant treatment regimens in female patients with locally advanced, inflammatory or early stage HER2 positive breast cancer.
- Trial name
- NCT00545688
- Testing
- Herceptin, Docetaxel, Pertuzumab
- Where
- 77 sites in Australia, Austria and 16 more
- Volunteers
- 417 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of Avastin (Bevacizumab) Plus Herceptin (Trastuzumab) in Patients With Primary Inflammatory HER2-Positive Breast Cancer.
This single arm study will assess the efficacy and safety of preoperative treatment with Avastin combined with Herceptin-based chemotherapy in patients with primary inflammatory HER2-positive breast cancer.
- Trial name
- NCT00717405
- Testing
- Standard chemotherapy, bevacizumab [Avastin], trastuzumab [Herceptin]
- Where
- 28 sites in France
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
TKI258 for Metastatic Inflammatory Breast Cancer Patients
The goal of this clinical research study is to learn if dovitinib can help to control inflammatory breast cancer. The safety of this drug will also be studied.
- Trial name
- NCT01262027
- Testing
- Dovitinib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms, Breast
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer
The double blind part of the study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with inflammatory breast cancer whose tumors overexpress…
- Trial name
- NCT00558103
- Testing
- lapatinib, Pazopanib
- Where
- 126 sites in United States, Australia and 26 more
- Volunteers
- 163 people
- Sponsor
- GlaxoSmithKline
Inflammatory Breast Cancer, Stage IIA Breast Cancer
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
This phase II trial studies how well carboplatin and nab-paclitaxel before surgery work in treating patients with triple negative breast cancer that is inflammatory or has spread from where it started to nearby tissue or lymph…
- Conditions
- Inflammatory Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT01525966
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- City of Hope Medical Center
Breast Cancer
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
The goal of this clinical research study is to learn how effective the combination of chemotherapy including both panitumumab, Abraxane (nab-paclitaxel), and carboplatin (PNC) and fluorouracil, epirubicin, and cyclophosphamide…
- Trial name
- NCT01036087
- Testing
- Panitumumab, Nab-paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms
Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer
The general aim of this study is to investigate the efficacy and safety of afatinib alone and in combination with weekly vinorelbine (in patients who progress on afatinib monotherapy within this trial) as treatment in patients…
- Trial name
- NCT01325428
- Testing
- Afatinib once daily (OD), Vinorelbine Weekly
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 26 people
- Sponsor
- Boehringer Ingelheim
Metastatic Breast Cancer, Breast Cancer
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
This study is to learn if the combination therapy of capmatinib and neritinib can help to control metastatic or locally advanced breast cancer.
- Trial name
- NCT05243641
- Testing
- Neratinib, Capmatinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Neoadjuvant Treatment of Breast Cancer
Study Aims 1. To measure the clinic response rates in patients with breast cancer more than 2 cm and/or lymph node positive breast cancer treated with 2-4 cycles of biweekly doxorubicin, cyclophosphamide with…
- Trial name
- NCT00254592
- Testing
- Doxorubicin, Cyclophosphamide, Carboplatin
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, Irvine
Recurrent Breast Cancer, Metastatic Breast Cancer
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
This phase I/II research study is evaluating a combination of drugs called paclitaxel and ruxolitinib as a possible treatment for inflammatory breast cancer.
- Trial name
- NCT02041429
- Testing
- Ruxolitinib, Paclitaxel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer
This single arm study will assess the efficacy and safety of sequential neoadjuvant chemotherapy and bevacizumab (Avastin), before surgery and/or radiotherapy, in participants with inflammatory or locally advanced operable breast…
- Trial name
- NCT00559845
- Testing
- 5-fluorouracil, Epidoxorubicin, Cyclophosphamide
- Where
- 8 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer
RATIONALE: Oxidized glutathione (NOV-002) may stimulate the immune system in different ways and stop tumor cells from growing. Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and docetaxel, work in different…
- Trial name
- NCT00499122
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- University of Miami
HER2/Neu Negative, Recurrent Inflammatory Breast Carcinoma
Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
The purpose of this research study is to look at the efficacy (the effect on tumor) and the safety (the effect on body) of the study drugs when given as a combination in patients with metastatic recurrent epidermal growth factor…
- Conditions
- HER2/Neu Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer, Stage IV Inflammatory Breast Carcinoma
- Trial name
- NCT02892734
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
This phase II trial studies how well talimogene laherparepvec works in treating patients with breast cancer that has come back and cannot be removed by surgery.
- Conditions
- Malignant Chest Wall Neoplasm, Recurrent Breast Carcinoma, Recurrent Inflammatory Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT02658812
- Testing
- Laboratory Biomarker Analysis, Talimogene Laherparepvec
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
In this trial we will evaluate ABI-007 with gemcitabine and epirubicin, utilizing the biweekly pegfilgrastim support, in order to further improve upon the effectiveness and favorable toxicity of this triplet.
- Trial name
- NCT00193206
- Testing
- Gemcitabine, Epirubicin, Albumin-bound Paclitaxel
- Where
- 13 sites in United States
- Volunteers
- 123 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
This single arm study will assess the efficacy and safety of combination first-line treatment with docetaxel + Xeloda + Avastin in patients with inflammatory or locally advanced breast cancer.
- Trial name
- NCT00576901
- Testing
- bevacizumab [Avastin], Docetaxel, Xeloda
- Where
- Spain
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche